3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Thyroidectomy
4
Iodine-131
4
trametinib
3
dabrafenib
3
apatinib
3
anlotinib
2
Surgical Procedures, Operative
2
Blood Specimen Collection
2
Biopsy, Large-Core Needle
2
toripalimab
1
tislelizumab
1
surufatinib
1
regorafenib
1
penpulimab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
famitinib
1
camrelizumab
1
Ultrasonography
1
Thyroxine
1
Thyrotropin Alfa
1
Sunitinib
1
Second Harmonic Generation Microscopy
1
Routinely Collected Health Data
1
Rosiglitazone
1
Robotic Surgical Procedures
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Thyroid Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled